Human Anti-IL-5 Antibodies With High-Affinity Specific Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting interleukin-5 (IL-5) for conditions like eosinophilic asthma and hypereosinophilic syndrome have limitations in efficacy and specificity, particularly in binding affinity and cross-reactivity with other cytokines.
Innovation Solution
Development of human antibody molecules with specific CDR sequences that immunospecifically bind to human IL-5 with an equilibrium affinity constant of at least 40 pM, providing enhanced potency and reduced cross-reactivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-IL-5 antibodies are used for treating eosinophilic conditions, then therapeutic effect is achieved, but binding affinity is insufficient and cross-reactivity with other cytokines occurs
Solution Approach 1:
The patent applies local quality by optimizing specific regions of the antibody molecule, namely the complementarity determining regions (CDRs), to achieve high-affinity binding to IL-5 while maintaining specificity. The CDR sequences are carefully designed and selected to interact precisely with the IL-5 epitope, improving binding affinity without causing cross-reactivity with other cytokines. This localized optimization at the antigen-binding interface resolves the contradiction between achieving therapeutic effect and avoiding cross-reactivity.
Solution Approach 2:
The patent employs parameter changes by systematically varying the amino acid sequences of the antibody CDRs to optimize binding characteristics. Through mutagenesis and sequence optimization, the patent adjusts parameters such as amino acid composition, CDR length, and sequence variability to achieve the desired balance between high-affinity binding and specificity. This parameter optimization enables the antibody to distinguish between IL-5 and other similar cytokines, resolving the cross-reactivity issue while maintaining therapeutic efficacy.
2Reliability
If antibody molecules with high binding affinity are designed, then potency is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody molecule into distinct functional regions: complementarity determining regions (CDRs) responsible for antigen binding and framework regions providing structural stability. This segmentation allows independent optimization of each region - the CDRs are designed for high-affinity binding to IL-5, while the framework regions are selected for ease of manufacturing and expression. By separating these functional requirements into distinct segments, the patent achieves high potency without proportionally increasing overall manufacturing complexity.
Solution Approach 2:
The patent employs universality by designing the antibody with standardized constant regions that can be produced using conventional recombinant DNA techniques, while incorporating optimized variable regions for high-affinity binding. The constant regions serve multiple functions: structural support, proper folding, and compatibility with standard manufacturing protocols. This universal design approach for the constant regions, combined with optimized variable regions, enables high-potency antibodies to be manufactured using existing infrastructure, thereby reducing the complexity increase that would otherwise result from designing entirely novel antibody structures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody molecules demonstrate improved potency in inhibiting IL-5-driven processes, such as eosinophil differentiation and airway eosinophilia, with sustained efficacy over prolonged periods.
Implementation Method 1
human antibody molecules that immunospecifically bind to human IL-5 with an equilibrium affinity constant (KD) of at least about 40 pM
Data Source
AI summary
Disclosed herein are fully human antibody molecules that immunospecifically bind to human IL-5. The antibody molecules can bind to human IL-5 with an equilibrium affinity constant (KD) of at least about 40 pM as determined by surface plasmon resonance.